|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 2, 2018 - Apr 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
PositiveID Corporation’s (“PositiveID” or “Company”) (PSID) ExcitePCR subsidiary today announced it successfully tested for Listeria bacterium on its FireflyDX breadboard prototype pathogen detection system (“prototype system”), being developed to detect pathogens at the point of need, which in this case could be a food processing facility. Listeria was amplified on the FireflyDX prototype system using fluorescence resonance energy transfer (FRET) chemistry. Listeriosis is a serious infection usually caused by eating food contaminated with the bacterium Listeria monocytogenes, most commonly found in dairy products and produce.
PositiveID Corporation (“PositiveID” or “Company”) (PSID) announced today its ExcitePCR subsidiary has joined Cambridge Healthtech Institute’s meeting of internationally recognized experts in detection and biological threats, Biodetection Technologies: Biothreat and Pathogen Detection, to be held in Bethesda, MD June 27-28th. ExcitePCR Chief Science Officer Kimothy Smith DVM, Ph.D., will participate in a discussion centered on cutting-edge strategies to overcoming hurdles to global biological threats defense and detection, and obstacles faced in getting detection technologies from lab to field, such as ExcitePCR’s FireflyDX family of point-of-care (POC) pathogen detection. ExcitePCR is developing the FireflyDX family of pathogen detection systems, portable devices offering rapid sample-to-result detection in less than 30 minutes using real-time polymerase chain reaction (PCR) chemistry at the point-of-need or point-of-care.
PositiveID Corporation (the “Company”) (PSID), a life sciences company focused on detection and diagnostics, announced today a new interview with Chairman and CEO William J. Caragol that details the Company’s private label distribution agreement, announced June 18th, with a global leader in non-invasive patient monitoring systems. In the interview, Caragol describes the Company’s development of the latest version of the Caregiver® non-contact thermometer and its expected impact on the Company’s medical device business. The FireflyDX family of products is being developed in both portable and handheld forms to provide accurate, rapid pathogen detection using real-time polymerase chain reaction (PCR) in less than 30 minutes, with minimally trained personnel and at a lower cost than existing systems.
Masimo and Thermomedics, a PositiveID company, announced today the debut and U.S. market release of TIR-1™, a non-contact Bluetooth®-enabled thermometer that integrates seamlessly with the Masimo Root® patient monitoring and connectivity platform.
PositiveID Corporation (“PositiveID” or “Company”) (PSID), a life sciences company focused on detection and diagnostics, announced today that its Thermomedics subsidiary will exhibit the Caregiver® non-contact thermometer at the Association for Professionals in Infection Control and Epidemiology (APIC) 2018 Annual Conference from June 13-15th at the Minneapolis Convention Center in Minneapolis, MN. Caregiver, FDA cleared for clinical use, is a professional grade, infrared thermometer that measures forehead temperature in adults, children, and infants, without contact. Infectious diseases like Ebola, Candida Auris, and others that can be spread from skin-to-skin contact stress the need to utilize thermometers and other medical devices that do not touch the patient thereby minimizing cross-contamination.
PositiveID Corporation (“PositiveID” or “Company”) (PSID) ExcitePCR subsidiary today announced publication of an article co-authored by Chief Science Officer Kimothy Smith, DVM, Ph.D., calling for an update of the previous critical effort to dismantle former Soviet nuclear weapons for the current threat of modern chemical and biological weapons of mass destruction, particularly in North Korea. The Democratic People’s Republic of Korea (DPRK) has the third largest stock of chemical weapons on the planet according to the article, including nerve, blister, blood, and vomiting agents. The next cooperative threat reduction program must be as focused on the chemical and biological threats as much or more than the nuclear threat, according to article authors.
PositiveID Corporation (“PositiveID” or the “Company”) (PSID), a life sciences company focused on detection and diagnostics, is proud to provide stockholders with the following 2018 mid-year corporate update, including details related to the Company’s key strategic and operational goals for its flagship FireflyDX and Caregiver products looking ahead to the second half of this year and beyond. William J. Caragol, Chairman and CEO of PositiveID, comments, “The first half of 2018 may go down as one of the most important times in the Company’s history. On April 26, 2018, the Company announced in a letter to stockholders that it was conducting negotiations with two potential strategic partners related to transactions that could fund the testing and development of the FireflyDX-Portable.